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Link4Health, a cluster-RCT, demonstrated the effectiveness of a combination strategy tar-
geting barriers at various HIV continuum steps on linkage to and retention in care; showing
effectiveness in achieving linkage to HIV care within 1 month plus retention in care at 12
months after HIV testing for people living with HIV (RR 1.48, 95% CI 1.19–1.96, p = 0.002).
In addition to standard of care, Link4Health included: 1) Point-of-care CD4+ count testing;
2) Accelerated ART initiation; 3) Mobile phone appointment reminders; 4) Care and preven-
tion package including commodities and informational materials; and 5) Non-cash financial
incentive. Our objective was to evaluate the cost-effectiveness of a scale-up of the Lin-
k4Health strategy in Swaziland.
Methods and findings
We incorporated the effects and costs of the Link4Health strategy into a computer simula-
tion of the HIV epidemic in Swaziland, comparing a scenario where the strategy was scaled
up to a scenario with no implementation. The simulation combined a deterministic com-
partmental model of HIV transmission with a stochastic microsimulation of HIV progression
calibrated to Swaziland epidemiological data. It incorporated downstream health costs
potentially saved and infections potentially prevented by improved linkage and treatment
adherence. We assessed the incremental cost-effectiveness ratio of Link4Health compared
to standard care from a health sector perspective reported in US$2015, a time horizon of 20
years, and a discount rate of 3% in accordance with WHO guidelines.[1] Our results suggest
that scale-up of the Link4Health strategy would reduce new HIV infections over 20 years by
11,059 infections, a 7% reduction from the projected 169,019 cases and prevent 5,313
deaths, an 11% reduction from the projected 49,582 deaths. Link4Health resulted in an
incremental cost per infection prevented of $13,310 and an incremental cost per QALY
gained of $3,560/QALY from the health sector perspective.
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Conclusions
Using a threshold of <3 x per capita GDP, the Link4Health strategy is likely to be a cost-
effective strategy for responding to the HIV epidemic in Swaziland.
Introduction
Swaziland has the highest prevalence of HIV in the world. With a population of 1.1 million
persons, Swaziland has an estimated adult (age 18–49 years) HIV prevalence of 31% and an
estimated HIV incidence of 2.4%.[2–4] The country has made impressive strides to respond to
the epidemic by increasing the number of HIV-positive adults on antiretroviral therapy (ART)
from 72,402 in 2011 to 147,274 in 2015.[5] However, evidence shows that linkage to and reten-
tion in care after ART initiation remains suboptimal.[6, 7]
In order to garner the individual and societal benefits from ART, HIV-positive individuals
must achieve all steps of the HIV care continuum.[8–11] The care continuum has been shown
to be fragile with critical gaps reported from multiple studies conducted in sub-Saharan Afri-
can countries including high attrition from testing to linkage to care and suboptimal retention
in ongoing care.[12–20] Despite the interdependent nature of the steps in the HIV care contin-
uum, most studies have only considered the effect of an individual intervention on one step in
the HIV care continuum,[21–24] and few have studied a combination approach that targets
multiple barriers along the continuum.[25]
The Link4Health Study, a cluster-randomized controlled trial that evaluated a combined
multi-intervention strategy aimed at various steps in the HIV care continuum demonstrated
significant improvement in the primary outcome of linkage to HIV care within 1 month of
HIV testing plus retention in care at 12 months after HIV testing for people living with HIV
(PLWH) in Swaziland (RR 1.48, 95% CI 1.19–1.96, p = 0.002).[26] The study compared stan-
dard of care alone with standard of care along with multiple evidence-based structural, bio-
medical, and behavioral interventions, including point of care CD4+ cell count testing, rapid
ART initiation, SMS visit reminders, financial incentives, and provision of health packages to
motivate linkage and retention. The study design was described previously.[26, 27]
Neither, the cost-effectiveness of the Link4health in Swaziland and similar contexts, nor
other similar multi-component interventions, however, have been assessed. We aimed to eval-
uate the cost-effectiveness of this scale-up through use of a computer simulation of HIV pro-
gression and transmission, comparing a scenario in which the Link4Health strategy was scaled
up with a counterfactual scenario with no implementation of the Link4Health strategy.
Methods
Analyses were performed using a combined stochastic natural history model and determin-
istic, compartment model of the HIV epidemic in Swaziland. A previously developed model of
HIV progression and transmission for east Africa [28] was modified to be calibrated to Swazi-
land epidemiological data and parameterized with the observed effects and costs of the Lin-
k4Health strategy (Table 1). Using the simulation, the impact and cost-effectiveness of a
nationwide scale-up of the Link4Health strategy in Swaziland was projected.
Model overview
The simulation is composed of two modules. The first module is a Monte Carlo microsimula-
tion of HIV progression that follows a cohort of HIV-positive individuals and predicts time
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Table 1. Key input parameters.
Description of parameter input Value References
Alcohol use
Prevalence of unhealthy alcohol use (Male/Female) 9.7%/2% [29]
Relative risk of unhealthy alcohol use on condom misuse or non-use 1.29 [30]
Relative risk of unhealthy alcohol use on non-HIV STIs 1.72 [30]
Relative risk of unhealthy alcohol use on non-adherence to ART 2.33 [30]
Sexual risk behaviors
Proportion abstinent (M/F) 5%/10% [31–34]
Proportion monogamous (M/F) 31%/69% [34–36]
Proportion in multiple, concurrent relationships (M/F) 56%/17% Assumption
Proportion who are clients of (men) or who are CSW (female) (M/F) 8%/4% [37, 38]
Frequency of sex acts (per year) 104 Assumption
Duration of relationship 1y-30y Assumption
Median number of concurrent partners- non CSW 3 [36]
Median number of concurrent partners- CSW 10 [36]
Probability of consistent condom use 56.8% [39]
Relative risk of unsafe sex (condom nonuse most or all of the time) if aware of
HIV status
0.47 [40]
HIV epidemiology and transmission
Adult HIV prevalence (1997) 20.9% [41]
Probability of transmission per sex act 0.00011–
0.01243
[42, 43]
Prevalence of circumcision among adult men 20% [39]
Modifier of male circumcision on F!M HIV transmission per sex act RR 0.6 [44]
Modifier of consistent condom use on HIV transmission per sex act RR 0.2 [45]
Untreated non-HIV STI prevalence 6% [46]
Probability of HIV testing 40% [39]
Probability of linkage to HIV care and treatment 50.3% [39]
Probability of adherence to ART regimen 84% [47]
Intervention effects and costs
Modifier of Intervention on Linkage and Retention RR 1.48 RCT
Outpatient care, per year, no ART (visits, SMS, BCPP, Financial incentives) $324 RCT
On Site CD4+ test available $26 RCT
Utilities
Decrease in utility with ART 0.053 [48]
Utility with CD4+ count < 50 cells/mm3 0.69 [49, 50]
Utility with CD4+ count between 50 cells/mm3 and 199 cells/mm3 0.79 [50]
Utility with CD4+ count200 cells/mm3 0.83 [50]
Other Costs (2015 US$)
Outpatient care, per year, without ART (non-intervention) $278 RCT
Hospitalization costs, per year $464 [51]
First-line ART, monthly $13 [52]
Second-line ART, monthly $28 [52]
Viral load test $35 [53]
CD4+ count test (non-intervention) $11 RCT
Abbreviations: STI, Sexually transmitted infection; CSW, Commercial sex worker; SMS, text messaging; BCPP, Basic
care and prevention package
https://doi.org/10.1371/journal.pone.0204245.t001
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until ART failure, accumulation of resistance mutations, and patient survival. Individuals
progress to AIDS and AIDS-related deaths at varying rates depending on whether they adhere
with ART and/or develop resistance to ART, based on viral load suppression and CD4+ cell
count trajectory. This progression module provides data to inform the second module, a trans-
mission model. This process is described in detail in the Supplementary Material.
In the second module, the transmission of HIV through the Swaziland population is pre-
dicted by a compartmental model. In the transmission module segments of a hypothetical pop-
ulation can become HIV infected, have their infection detected, and access treatment, which
can modify their infectivity. Segments of this population can also modify their risk of transmis-
sion by exhibiting behaviors including ART adherence, multiple sexual partnerships, failing to
use condoms, and having STIs. For example, an intervention may lead to improved ART
adherence, which lowers viral load and extends life expectancy in the progression module. The
lowered viral load then decreases the risk of transmitting HIV in the transmission module.
Transmission model compartments are stratified by age, sexual activity level, excessive alcohol
use, HIV status, and if infected, viral load, CD4+ cell count, and ART resistance pattern.
Model calibration did not prioritize individual parameters, but sought to minimize the least
squares across the parameters as a whole. The design of the simulation, as well as its calibration
and validation, is described in more detail in the Supplementary Material and elsewhere.[28]
We used the calibrated simulation to evaluate the impact and value of the Link4Health strategy
in Swaziland. The simulation was calibrated to Swaziland epidemiological data with the goal of
replicating trends in Swaziland HIV prevalence, incidence, deaths, and PLWH from 1997 to
2015 (Fig 1).[41, 54, 55] Therefore, model inputs, such as HIV prevalence, reflect 1997 HIV
data representing the start of the calibration period. The model inputs and the intervention
effects are described in more detail in Table 1.
The Link4Health strategy was represented in the simulation by a specific set of HIV trans-
mission “pathways” through which it could exert an effect, along with the corresponding target
population (e.g. all HIV-positive adults), and an estimated cost per person per year. The effect
of the Link4Health strategy (RR 1.48 for linkage to and retention in care) was represented in
the transmission model as a multiplier that accelerated pathways for linkage to care and
enhanced retention in treatment, in accord with the observed effect size in the study (Fig 2).
The effect on linkage and retention was applied to current HIV patients and new HIV diagno-
ses continuously while the strategy was active. Link4Health also impacts QALYs gained by
increasing linkage to and retention in care. The model applied the viral load decrement that is
expected with care retention versus non-retention to influence that person’s HIV course (and,
therefore, that person’s QALYs), as well as that person’s likelihood of transmitting HIV (and,
therefore, other persons’ QALYs). We conservatively assumed that effects only persisted while
the strategy was continued.
Outcomes measured included total quality-adjusted life years (QALYs), incremental cost
effectiveness ratios (ICERs), number and proportion of new HIV infections prevented and
incremental cost per infection averted. Incremental outcomes compared standard of care to
standard of care plus the Link4Health intervention. Link4Health cost data was collected pro-
spectively at the time of the trial and represent actual in-trial costs for standard of care and the
Link4Health intervention, including the cost of training staff implementing the Link4Health
intervention (Table 2). Uncertainty ranges around trial costs were unavailable as all study sites
were Ministry of Health (MoH) health facilities with MoH funded staff with defined salaries,
and all lab testing were done on a pre-determined schedule based on national guidelines and
performed either at the facility or the national laboratory. Consequently, there was little to no
variation in treatment costs across study sites. Research-specific costs, such as material devel-
opment, were not included in the analysis. Non-trial specific costs, including treatment and
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hospitalization costs were derived from the literature (Table 1). Trial costs were converted
from Swazi lilangeni into US dollars and along with cost data collected from the literature
were converted into 2015 US dollars using the consumer price index.[56] Costs and effects
were discounted at 3%, our time horizon was 20 years, and costs were assessed from a health
sector perspective using 2015 US dollars. Other than specifying a finite time horizon, all other
aspects of the cost-effectiveness analysis were conducted in line with recommendations by the
Panel on Cost-Effectiveness in Health and Medicine.[57] We chose a 20-year rather than infi-
nite time horizon because we found that it was the longest time horizon viewed as credible by
stakeholders. A population of 1,098,575 was simulated representing the population of Swazi-
land at the start of the calibration period in 1997.
Link4Health intervention
The Link4Health study was a cluster randomized controlled trial performed from 2013 to 2015
in Swaziland that compared standard of care (N = 1,101) to the Link4Health combination
strategy plus standard of care (N = 1,096).[26] As noted above, the Link4Health strategy incor-
porated multiple evidence-based structural, biomedical, and behavioral interventions to
improve linkage to and retention in care among adults with HIV in Swaziland. In addition to
standard of care, the five interventions combined as package in the Link4Health strategy
Fig 1. Calibration (A) Number of persons living with HIV, (B) Number of HIV Deaths. A. NOTE: The singular point
represents the prevalence found in the 2011 population survey. High and low estimates are from UNAIDS. B.NOTE: High and low
estimates are from UNAIDS.
https://doi.org/10.1371/journal.pone.0204245.g001
Fig 2. Link4Health impact on model pathways.
https://doi.org/10.1371/journal.pone.0204245.g002
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included: 1) Point-of-care CD4+ count testing. 2) Accelerated ART initiation for eligible par-
ticipants (CD4+ count 350 cells/mm3 or WHO Stage III/VI) to enable ART initiation within
1 week of diagnosis. 3) Mobile phone appointment reminders. 4) Basic care and prevention
package including commodities and informational materials. 5) Non-cash financial incentive
for who linked to care within 1 month of HIV testing and those who completed HIV care
clinic visits at 6 and 12 months after HIV testing (Table 2). Swazi decision makers were
involved at each step of the Link4Health trial and cost-effectiveness analysis and provided
guidance to ensure the Link4Health strategy and its analyses were relevant to the Swazi HIV
program goals.
Cost-effectiveness analysis
As a base case analysis we conducted simulations where the Link4Health strategy was activated
and calculated the health benefits, costs, and cost-effectiveness ratios of each over the twenty
year time horizon. These simulations were compared to a scenario where no additional inter-
ventions were implemented. As a sensitivity analysis we varied both intervention efficacy and
cost independently across plausible ranges and evaluated their impact on cost-effectiveness.
Table 2. In trial costs per patient and component descriptions.














• Standard CD4+ test after initial HIV
diagnosis
• Turnaround time approximately 2
weeks
• 1 additional clinic visit required to
return lab results to patient (15 min
staff time of nurse)
$11.40 • Point-of-care CD4 assays at the HIV testing site at the
time of HIV testing
• Turnaround time immediate
• Accelerated ART initiation for patients with point-of-
care CD4+ count 350 cells/mm3 within 1 week from
testing
• On site CD4+ test. No staff time for duration of test
processing included as routine counseling occurs during
processing time; testing supplies; 5 mins for blood draw
$25.80
Outpatient care $278 $324
Outpatient visit - Average cost for standard appointment
for ART patients and pre-ART patients,
not including treatment
$266.50 Average cost for standard appointment for ART patients







• Standard CD4+ test after initial HIV
diagnosis
• Turnaround time approximately 2
weeks
• 1 additional clinic visit required to
return lab results to patient (15 min
staff time of nurse)
$11.40 • Point-of-care CD4 assays at the HIV testing site at the
time of HIV testing
• Turnaround time immediate
• Accelerated ART initiation for patients with point-of-
care CD4+ count 350 cells/mm3 within 1 week from
testing
• On site CD4+ test. No staff time for duration of test
processing included as routine counseling occurs during




Linkage, retention - - • SMS visit reminders 3 days prior to each scheduled visit




Retention - - • A health education package every 3 mo. at visits.
Included condoms, soap, cotrimoxazole, a pill box, and
pictorial education about use of materials and HIV




Linkage, retention - - • Mobile phone credit for those linked to care within 1
month and those completing HIV care clinic visits at 6
and 12 mo. of HIV testing
• Mobile phone credit, staff time
$29.14
Abbreviations: ART, antiretroviral therapy; SMS, short message service
https://doi.org/10.1371/journal.pone.0204245.t002
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Plausible ranges were determined using trial 95% confidence intervals for effectiveness. It was
technically infeasible to do a probabilistic sensitivity analysis as the simulation involves infor-
mation exchange between a compartmental model and a microsimulation and the run times
would be prohibitively long. Between 2013 and 2018 the economic discount rate established by
the Central Bank of Swaziland has ranged from 5% to 7.25%.[58] The economic discount rate
has been suggested as a surrogate for the social discount rate in developing countries,[59]
therefore to encapsulate alternate discount rates that are relevant to Swazi decision making, we
also performed sensitivity analyses ranging the discount rate from 5 to 8%. Additionally, in
line with evolving ART initiation recommendations, we performed a secondary analysis to
simulate the effectiveness of the strategy under the scenario of universal ART adoption, thus
eliminating CD4+ testing costs and starting all HIV-positive individuals on ART immediately.
We then simulated the Link4Health strategy and calculated the ICERs of the intervention.
ICERs measure the additive benefit of each strategy compared with its next best alternative,
and interpret this benefit together with its additive cost. A cost per QALY gained value less
than three times the per capita GPD (~$9,840) was considered likely to have favorable cost




In the base case analysis, the Link4Health strategy reduced the number of new HIV infections
over 20 years by 11,059 (6.5%) for total of 157,961 versus 169,019 new infections in Swaziland
(Fig 3A) and the HIV prevalence in adults decreased by 0.7% from 20.9% to 20.2% (Fig 3B).
The number of HIV-related deaths over 20 years was reduced by 5,313 from 49,582 to 44,270
deaths (Fig 3C).
Cost effectiveness
When implemented using a health sector perspective, the Link4Health strategy resulted in a
total additional cost of $195,700,677 (Fig 2D) and a total discounted additional cost of
$147,197,723 over 20 years. Over 20 years the discounted cost per HIV infection prevented
was $13,310. Over a 20-year time horizon, the discounted cost per QALY gained was $3,560.
Using time horizons of 10 years and 5 years rather than 20 years increased the discounted
incremental cost-effectiveness ratio of the Link4Health strategy to $7,195/QALY and $14,122/
QALY, respectively, (Table 3) as the costs were mostly borne early whereas the benefits
(lengthened life and reduced transmission) mostly occurred later. The discounted cost-effec-
tiveness of Link4Health strategy over 20 years at the highest and lowest range of the 95% confi-
dence interval of intervention effectiveness was $5,572/QALY and $2,911/QALY, respectively.
Sensitivity analyses
In one-way and multi-way sensitivity analyses, results regarding costs and benefits were highly
stable, with the Link4Health strategy remaining cost effective and improving health across a
range of assumptions. In sensitivity analyses to determine the threshold at which Link4Health
is no longer cost-effective, reducing the per-patient cost of the Link4Health strategy by 7%
(-$8) from baseline ($108) decreased the ICER to make the intervention very cost effective
($/QALY<GPD/Capita) (Fig 4). Reducing the cost by 87% (-$94) made the Link4Health
strategy cost-saving (Fig 4). Increasing the strategy cost by 154% (+$166) made the strategy
not cost-effective ($/QALY>3xGPD/Capita). The model results were more sensitive to
Cost-effectiveness of Link4Health
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programmatic costs than the cost of care and treatment. Similarly, decreasing strategy effec-
tiveness by 15% decreased new infections averted to 872 infections and HIV deaths to 3,277,
decreased discounted QALYs gained to 19,014 QALYs, and made the strategy no longer cost-
effective. Increasing the strategy effect size by 4% increased infections averted to 12,603 infec-
tions and HIV deaths to 6,055, increased discounted QALYs gained to 44,751 QALYs, and
Fig 3. Undiscounted change in (A) HIV Prevalence, (B) Number of new infections, (C) Number of HIV-related Deaths, and (D) Undiscounted cost and undiscounted
QALYs gained.
https://doi.org/10.1371/journal.pone.0204245.g003
Table 3. Cost-effectiveness by time horizon.
Total Costs (Discounted) Total Discounted QALYs Cost Change QALYS Gained (Discounted) ICER ($/QALY)
20 Yr. Horizon
Standard Care $1,263,589,463 19,314,636 - - -
Link4Health $1,410,787,186 19,355,978 $147,197,723 38,597 $3,919
10 Yr. Horizon
Standard Care $711,420,043 10,529,352 - - -
Link4Health $794,361,248 10,540,879 $82,941,205 10,904 $7,686
5 Yr. Horizon
Standard Care $379,390,695 5,540,162 - - -
Link4Health $421,639,679 5,543,153 $42,248,984 2,894 $14,626
https://doi.org/10.1371/journal.pone.0204245.t003
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made the strategy very cost-effective (Fig 4). Universal ART decreased the discounted ICER to
$2,211/QALY. Increasing the discount rate to 5% and 8% resulted in an ICER of $3,832/QALY
and $4,286/QALY, respectively.
Discussion
We provide projections of the impact and cost-effectiveness of a scale up of a combination
strategy of multiple interventions targeting barriers at various HIV continuum steps for link-
age to and retention in care among HIV-positive individuals in Swaziland. Few studies have
evaluated a combination approach that includes multiple interventions bundled into a coher-
ent strategy that would target numerous barriers along the HIV care continuum,[23, 25, 27,
61] and the cost-effectiveness of such an approach has not previously been evaluated.[62] Our
analyses suggest that from a health sector perspective, a scale-up of the Link4Health combina-
tion strategy is likely to be cost-effective. Our findings were robust over a range of assumptions
regarding cost and effectiveness and the strategy was found to remain cost-effective at shorter
time horizons such as 10 years. Examining a range of time horizons demonstrated the poten-
tial to underestimate the cost-effectiveness of HIV interventions when only considering
shorter horizons due to the frequent longer-term health and cost implications of diseases like
HIV/AIDS.
The Link4Health study represents the first study that evaluated multiple interventions pack-
aged in one strategy on both linkage to care and retention in care. Previous studies have found
Fig 4. Discounted cost-effectiveness sensitivity analysis.
https://doi.org/10.1371/journal.pone.0204245.g004
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individual elements that increase linkage and retention in care to be cost-effective in other
low- and middle- income nations in Africa.[63–65] The cost-effectiveness of the Link4Health
strategy falls within the range observed in these single intervention studies, being more cost
effective than point of care testing alone ($4,468/DALY),[63] but not quite as cost effective as
text messaging alone ($1,024/QALY [adjusted to USD2015]) if DALYs are considered a surro-
gate for QALYs.[65] This demonstrates the potential benefits of a multicomponent strategy for
achieving a greater and more cost-effective impact on the care continuum than implementing
standalone interventions. With the potential to further decrease the Link4Health strategy
costs, the multicomponent strategy may prove to be the dominant choice for HIV care contin-
uum interventions. A decline in HIV prevalence is projected in Swaziland, even with standard
of care, and Link4Health magnifies this decline, which is in large part attributable to the
increasing population of Swaziland and low incidence of HIV in new births. Prior to the Lin-
k4Health study, there was substantial reluctance to rapidly initiate ART. The Link4Health
study, however, has already had a strong influence on the adoption of rapid initiation of ART
by the Swazi National AIDs Control Program, thus indicating the interest from stakeholders
in incorporating Link4Health-like strategies into the Swazi HIV program. Despite interest in
the program and its cost effectiveness as a care continuum intervention, a wide-scale imple-
mentation of the Link4health strategy may not be feasible until Swaziland has achieved univer-
sal ART coverage at the CD4+ count 500 cells/mm3 threshold. While Swaziland has
achieved universal ART coverage under the 2010 WHO guidelines (CD4+ count 350 cells/
mm3), it has not achieved universal ART coverage at the CD4+ count 500 cells/mm3 thresh-
old.[66] Therefore, HIV funds may not be available as they are diverted to the more cost effec-
tive implementation of universal ART coverage at the CD4+ count 500 cells/mm3 threshold
($245 to $1,746/DALY [adjusted to USD2015]).[67]
The largest portion of program costs was incurred through ART treatment costs, followed
by outpatient care, and the cost of CD4+ count testing. Therefore, there is potential to reduce
the cost of the HIV treatment program through reductions in the cost of outpatient care and
CD4+ count testing as HIV programs shift to differentiated models of care in which stable
HIV patients on ART may decrease the number and or frequency of clinic visits and universal
ART initiation replacing the need for CD4+ count testing. For example, in some resource-lim-
ited settings, patients who achieve viral suppression and are clinically stable receive ongoing
HIV care, including medications, in community adherence clubs, which decrease the number
of clinic visits.[68, 69] The 2015 Swaziland HIV strategy supports the development of HIV
support groups, however universal test and treat, while under consideration, is not part of
current HIV guidelines.[66] Further reductions in program costs are likely feasible because,
while financial incentives have shown promise in increasing HIV treatment in some interven-
tions,[70] a comparable level of effectiveness to that in the Link4Health study was found in a
trial performed in Mozambique of a similar intervention that did not include the financial
incentive component.[71] Removing the financial incentives from the Link4Health strategy
has the potential to decrease the strategy cost by nearly 30% and result in an even more
favorable cost-effectiveness at<1 times the GDP. The adoption of “treat-all” WHO recom-
mendations in Swaziland may eliminate the need for CD4+ count testing, reducing program-
matic costs by nearly 25% and improving potential cost-effectiveness to $2,211/QALY (Fig 4).
[72]
Our analysis has a number of limitations. First, because of the compartmental nature of the
transmission model, the effect on retention in care was represented through improvement of
ART adherence and does not account for the other potential benefits gained such as access to
other clinical assessments and health counselling. As a result, our analyses may underestimate
the total health benefits generated by the Link4Health strategy. Second, the analysis included
Cost-effectiveness of Link4Health
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the same strategy costs for all individuals enrolled in the study, including those that did not
ultimately receive the full intervention. This, however, likely overestimates the total cost of
implementation as individuals not in HIV care would not incur the full strategy cost. Similarly,
we assumed that HIV care visit costs would be the same for patients both on ART and those
not on ART. In practice, however, these costs may differ due to factors such as the professional
level of the healthcare worker. These differences in visit costs, however, are likely to be negligi-
ble when the cost ART treatment is considered. Third, not all model inputs were available for a
Swazi-specific setting, which may impact cost-effectiveness. During model validation, the
model was permitted to fit some indicators better than others in order to avoid overfitting to a
particular data source. The robust cost-effectiveness results across sensitivity analyses, how-
ever, indicate that minor variations in these inputs are unlikely to substantially affect the
results. Fourth, the Link4Health strategy was carried out in a population that has high preva-
lence of HIV compared to other countries in the world. Consequently, our results may not be
applicable to other populations. Further testing is needed to investigate the Link4Health strat-
egy’s effectiveness in populations outside of high HIV prevalence countries and contexts. Fifth,
the nature of the Link4Health trial, which examined the implementation of a package of inter-
ventions together and did not isolate the impact of each component separately, made this anal-
ysis unable to estimate how each component individually affects the cost-effectiveness of the
combined strategy. Similarly, due to the model structure it is not technically feasible to sepa-
rate how annuals costs will accrue for each relevant budget holder. Finally, it is worth noting
that the use of a cost-effectiveness threshold of<3 x per capita GDP, while transparent and
easily applied, is insufficient to determine whether an intervention should be implemented.
The more relevant cost-effectiveness threshold would be the incremental cost-effectiveness
ratio of simultaneously resource constrained interventions, as the health gained from any addi-
tional funds allocated towards on Link4Health would likely exceed the health lost from remov-
ing funds from other interventions.
Conclusion
The scale-up of the Link4Health strategy would substantially reduce HIV-related deaths and
avert new HIV infections. With a favorable value over a 10 year timeframe or longer, using a
threshold of<3 x per capita GDP, the Link4Health strategy could be a cost-effective strategy
for confronting the HIV epidemic in Swaziland and other low-income countries with a gener-
alized HIV epidemic. Efforts to strategically reduce strategy costs could lead to Link4Health





Human subjects: No human subjects were involved in this research project. Secondary data
only was used in the performance of this cost effectiveness analysis and all data were fully
anonymized prior to accessing them for this study. The NYU School of Medicine IRB deter-
mined the study to be non-human subjects and did not require informed consent. The original
Link4Health study was performed separately and was approved by the Columbia University
IRB.
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